Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 97

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 97
---
cement agreement that we entered into with certain investors in February 2025, we are obligated to file
a registration statement to register the shares of Common Stock issuable upon exercise of the new warrants within 45 days of the date
of such agreement and to use commercially reasonable efforts to keep the registration statement effective at all times while the investors
own any warrants or shares of Common Stock issuable upon exercise of the warrants. The failure to take any of these actions will constitute
a default under the warrant inducement agreement.

The
financial and operational projections that we may make from time to time are subject to inherent risks.

The
projections that we provide herein or our management may provide from time to time (including, but not limited to, those relating to
potential peak sales amounts, clinical and regulatory timelines, production and supply matters, commercial launch dates, and other
financial or operational matters) reflect numerous assumptions made by management, including assumptions with respect to our
specific as well as general business, regulatory issues, economic, market, and financial conditions and other matters, all of which are
difficult to predict and many of which are beyond our control. Accordingly, there is a risk that the assumptions made in preparing
the projections, or the projections themselves, will prove inaccurate. There may be differences between actual and projected
results, and actual results may be materially different from those contained in the projections.

 47 

Our
stock price has fluctuated in the past, has recently been volatile, and may be volatile in the future, and as a result, investors in
our Common Stock could incur substantial losses.

Investors
should consider an investment in our Common Stock risky and invest only if they can withstand a significant loss and wide fluctuations
in the market value of their investment. Investors who purchase our Common Stock may not be able to sell their shares at or above the
purchase price. Our stock price has been volatile and may be volatile in the future. The stock market in general has been, and the market
price of our Common Stock or Tradeable Warrants in particular, will likely be subject to fluctuation, whether due to, or irrespective
of, our operating results and financial condition. The market price of our Common Stock or Tradeable Warrants may fluctuate as a result
of a number of factors, some of which are beyond our control, including, but not limited to:

    ●
    actual
    or anticipated variations in our and our competitors’ results of operations and financial condition;